Advertisement

Picture ConsulTech GmbH RnD Credit Germany 650x80px
Employment/Membership › Details

NovaGo Therapeutics–Metcalfe I: management, 202009– CEO before Corlieve Therapeutics + Roche + Nestlé Health Science + Berna Biotech

 

Period Period 2020-09-21
Organisations Organisation NovaGo Therapeutics AG
  Organisation 2 Corlieve Therapeutics
Products Product anti-Nogo-A antibody
  Product 2 drug development
Persons Person Metcalfe, Ian (NovaGo Therapeutics 202009– CEO before Corlieve Therapeutics + Roche + Nestlé Health Science)
  Person 2 Vianna, Eduardo (NovaGo Therapeutics 202009– Chief Development Officer before CEO)
     

NovaGo Therapeutics AG. (9/21/20). "Press Release: NovaGo Therapeutics Appoints Ian Metcalfe as CEO". Schlieren.

> Over 20 years of experience focused on pharma and biotech

> Primary goal to deliver clinical proof-of-oncept in ophthalmology, enabled by securing series B funding


NovaGo Therapeutics, a development stage biotech company with a proprietary platform to stimulate blood vessel and nerve growth, today announced the appointment of Ian Metcalfe as the company’s Chief Executive Officer. He succeeds Eduardo Vianna, who becomes Chief Development Officer.

Ian joins at a pivotal time in NovaGo’s development, as it prepares to move into clinical proof-of-concept studies. He will be instrumental in securing the next round of funding, to finance this transition to a clinical-stage company and enabling further development of NovaGo’s proprietary anti-Nogo-A antibody platform.

With over 20 years of business experience across various industries centred on biotech and healthcare, Ian brings new expertise to the Board and Management team. He has successfully delivered results across many business development and strategic initiatives, while building strong trusted relationships with investors. Ian has held roles of increasing responsibility at Berna Biotech, Roche, Nestlé, Nestlé Health Science, and Corlieve Therapeutics, working across the development value chain from preclinical research to late stage development, commercialization and partnering.

"Ian’s breadth and depth of business experience will be a perfect complement to the scientific expertise of NovaGo’s founding team," said Dr Dominik Escher, Managing Partner at Pureos Bioventures and Board member of NovaGo. "The addition of his knowledge and capabilities enhances NovaGo’s ability to maximise its platform and bring new therapies to the clinic."

Ian Metcalfe, CEO of NovaGo said, “This is a unique opportunity to build on the strong scientific foundations that the NovaGo team has already established, taking our lead programme in ophthalmology into clinical development. Subject to successful financing and pre-clinical development, our goal is to have an IND for our first anti-Nogo-A antibody in 2021.”

Prof Martin Schwab, Founder and President of NovaGo said,“I look forward to working with Ian and thank Eduardo Vianna for bringing NovaGo successfully to this point. I am delighted that Eduardo will continue with the company in the role of Chief Development Officer. Ian and Eduardo together constitute a very strong management team, with the complimentary skills to maximize the potential of our platform for the benefit ofpatients.”


About NovaGo Therapeutics

Founded in 2015 in Schlieren, Switzerland, NovaGo Therapeutics is a development stage biotech company focused on human antibody therapeutics targeting blood vessel growth, nerve growth, and regeneration. In March 2019 NovaGo successfully closed a Series A financing round of CHF 10 million (USD11 million) led by Pureos Bioventures and Neurimmune.

The founders,management,and advisors have a proven track record in research and drug development. Existing collaborations and networks with partners in industry, academia, and the medical community have enabled rapid advancement of the NovaGo programmes.

NovaGo’s proprietary human antibodies, discovered using Neurimmune’s Reverse Translational Medicine™ technology, have the potential to become a safe and effective treatment in ophthalmology and central nervous system indications. NovaGo’s proprietary antibodies block the function of Nogo-A, one of the most potent and well-studied vascular and nerve growth inhibitors.

In 2021 NovaGo is planning to initiate clinical development in patients with diabetic retinopathy, the leading cause of blindness in adults. Future indications include cerebral stroke and spinal cord injury.

   
Record changed: 2020-09-23

Advertisement

Picture [iito] Männer Ballett 650x80px

More documents for NovaGo Therapeutics AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [iito] No Content Marketing 650x80px




» top